Learning objectives
Join us if you want:
- To better understand how the Intrepid™ TMVR system design facilitates the treatment of mitral regurgitation
- To learn about the Intrepid™ 29Fr TMVR system and the status of the APOLLO-EU trial
- To gain insights into the Intrepid™ clinical program with a data deep-dive
- To understand the long-term durability of the Intrepid™ TMVR system
Agenda
| Time | Intervention title | Faculty |
|---|---|---|
| 12:30 | Welcome and session objectives | Ralph Stephan Von Bardeleben |
| 12:32 | The Intrepid™ TMVR system design |
Ralph Stephan Von Bardeleben |
| 12:40 | Data deep-dive: Intrepid™ 5-year pilot transapical outcomes | Michael Reardon |
| 12:48 | Intrepid™ TMVR trial status and integrating the 29Fr system |
Thomas Modine |
| 12:56 | Discussion and audience interaction |
All panelists |
| 13:05 | APOLLO-EU 29Fr case review #1 | Paolo Denti |
| 13:13 | APOLLO-EU 29Fr case review #2 |
Daniel Blackman |
| 13:21 | Discussion and audience interaction | All panelists |
| 13:28 | Session evaluation and key learnings | Ralph Stephan Von Bardeleben |